REVIEW article

Front. Cardiovasc. Med.

Sec. Atherosclerosis and Vascular Medicine

Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1497938

HNRNPA2B1: A Novel Target in Pulmonary Arterial Hypertension

Provisionally accepted
Yingying  WeiYingying Wei1Daiqin  WuDaiqin Wu2Na  DengNa Deng1Fujia  XuFujia Xu1Sihan  LuoSihan Luo1Xinxin  FanXinxin Fan1Haijun  GuoHaijun Guo1Jingjing  ChenJingjing Chen2Wei  LiWei Li2*Xiaoyun  SiXiaoyun Si2*
  • 1Guizhou Medical University, Guiyang, Guizhou Province, China
  • 2Affiliated Hospital of Guizhou Medical University, Guiyang, China

The final, formatted version of the article will be published soon.

Purpose of Review: Pulmonary arterial hypertension (PAH) is a progressive clinical syndrome characterized by pulmonary vascular remodeling and elevated pulmonary artery pressure, associated with high morbidity and mortality. While targeted therapies have improved patient prognosis, restoring normal hemodynamics and reversing vascular pathology remain unmet challenges. Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1), an RNA-binding protein integral to mRNA processing and posttranscriptional regulation, governs critical processes including cell proliferation, apoptosis, angiogenesis, and endothelial homeostasis. However, its role in PAH pathogenesis remains poorly defined. This review synthesizes current evidence on HNRNPA2B1 in PAH, evaluates its potential mechanistic contributions, and discusses therapeutic implications. Given the fact that much of the connections between PAH and HNRNPA2B1 are speculative, rigorous mechanistic studies are imperative to clarify its pathobiological relevance.Recent Findings Emerging preclinical evidence suggests that HNRNPA2B1 silencing attenuates monocrotaline (MCT)-induced pulmonary hypertension (PH) in rat models. Mechanistically, HNRNPA2B1 modulates vascular smooth muscle cell (VSMC) proliferation via cross-talk between multiple signaling cascades and macrophage polarization dynamics, both central to pulmonary vascular remodeling. Nevertheless, clinical translatability remains uncertain, as no studies have yet conclusively validated HNRNPA2B1 as a druggable target in human PAH.Summary Recent evidence suggests HNRNPA2B1 has emerged as a potential therapeutic target for PAH.However, further studies are essential to elucidate its role in modulating the pathogenic mechanisms underlying PAH.

Keywords: arterial hypertension, HNRNPA2B1, vascular remodeling, smooth muscle cells, endothelial cell

Received: 21 Sep 2024; Accepted: 10 Jun 2025.

Copyright: © 2025 Wei, Wu, Deng, Xu, Luo, Fan, Guo, Chen, Li and Si. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Wei Li, Affiliated Hospital of Guizhou Medical University, Guiyang, China
Xiaoyun Si, Affiliated Hospital of Guizhou Medical University, Guiyang, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.